Clinical trial · Observational
PET-CT Predicting Lymph Nodes Metastasis
The Value of PET-CT in Predicting Lymph Nodes Metastasis in Non Small Cell Lung Cancer
NCT05970913CI-TRIAL-00106221active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a single-center prospective clinical study that aims to evaluate the predictive value of preoperative 18F-FDG-PET-CT and 18F-FAPI-PET/CT for lymph node metastasis in patients with non-small cell lung cancer. The final pathological results were used to assess the predictive value of PET-CT for lymph node metastasis.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymph Node Metastasis | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Positron Emission Tomography | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Predictive value of 18F-FDG-PET/CT and 18F-FAPI-PET/CT for lymph node metastasis
- timeFrame
- from enrollment to 1 month after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion. * Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1. * Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery. * No prior radiotherapy or chemotherapy for initial treatment. * No history of malignant tumors. Exclusion Criteria: * Locally advanced or distant metastasis. * Pleural dissemination observed during surgery. * History of malignant tumors. * Received neoadjuvant therapy. * Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).
References
Publications (0)
Data not yet available
No reference posted for this study.